Confirmation of a metastasis-specific microRNA signature in primary colon cancer

• Published in: Scientific reports Vol. 8; no. 1; pp. 5242 - 11
• Main Authors: Coebergh van den Braak, Robert R. J, Sieuwerts, Anieta M., Lalmahomed, Zarina S., Smid, Marcel, Wilting, Saskia M., Bril, Sandra I., Xiang, Shanshan, van der Vlugt-Daane, Michelle, de Weerd, Vanja, van Galen, Anne, Biermann, Katharina, van Krieken, J. Han J. M, Kloosterman, Wigard P., Foekens, John A., Martens, John W. M., IJzermans, Jan N. M.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 27-03-2018; Nature Publishing Group
• Subjects: 38/77; 692/4028/67/1504/1885/1393; 692/4028/67/1857; 692/53/2422; Aged; Aged, 80 and over; Axon guidance; Biomarkers, Tumor - genetics; Cancer therapies; Cell adhesion; Cell migration; Chemotherapy; Chemotherapy, Adjuvant; Colon cancer; Colonic Neoplasms - diagnosis; Colonic Neoplasms - drug therapy; Colonic Neoplasms - genetics; Colonic Neoplasms - pathology; Colorectal cancer; Colorectal carcinoma; Female; Gene expression; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humanities and Social Sciences; Humans; Liver Neoplasms - diagnosis; Liver Neoplasms - drug therapy; Liver Neoplasms - genetics; Liver Neoplasms - secondary; Male; Metastases; Metastasis; MicroRNAs; MicroRNAs - genetics; Middle Aged; miRNA; multidisciplinary; Neoplasm Metastasis - diagnosis; Neoplasm Metastasis - drug therapy; Neoplasm Metastasis - genetics; Neoplasm Recurrence, Local - diagnosis; Neoplasm Recurrence, Local - drug therapy; Neoplasm Recurrence, Local - genetics; Neoplasm Recurrence, Local - secondary; Patients; Prognosis; Prospective Studies; Science; Science (multidisciplinary); Tumors
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-018-22532-1

The identification of patients with high-risk stage II colon cancer who may benefit from adjuvant therapy may allow the clinical approach to be tailored for these patients based on an understanding of tumour biology. MicroRNAs have been proposed as markers of the prognosis or treatment response in colorectal cancer. Recently, a 2-microRNA signature (
l
et-7i
and
miR-10b
) was proposed to identify colorectal cancer patients at risk of developing distant metastasis. We assessed the prognostic value of this signature and additional candidate microRNAs in an independent, clinically well-defined, prospectively collected cohort of primary colon cancer patients including stage I-II colon cancer without and stage III colon cancer with adjuvant treatment. The 2-microRNA signature specifically predicted hepatic recurrence in the stage I-II group, but not the overall ability to develop distant metastasis. The addition of
miR-30b
to the 2-microRNA signature allowed the prediction of both distant metastasis and hepatic recurrence in patients with stage I-II colon cancer who did not receive adjuvant chemotherapy. Available gene expression data allowed us to associate
m
iR-30b
expression with axon guidance and
l
et-7i
expression with cell adhesion, migration, and motility.